| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 7 | +71.43% | +10.97% | -0.63% | +11.60% | -4.19% | — |
| 14d | 7 | +71.43% | +9.77% | -0.63% | +10.39% | -5.54% | — |
| 30d | 7 | +71.43% | +8.01% | -0.95% | +8.97% | -5.91% | — |
| 60d | 7 | +57.14% | +1.24% | +2.13% | -0.89% | -16.43% | — |
| 90d | 7 | +71.43% | -10.09% | +3.89% | -12.66% | -10.34% | — |
| 180d | 7(1 pending) | +83.33% | -14.49% | +6.93% | -19.16% | -16.81% | — |
| 1y | 7(3 pending) | +100.00% | -20.34% | +18.23% | -38.57% | -41.87% | — |
| 2y | 7(7 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 2,884 | $1.30 | $3.7K | 208,491 | Jun 5, 2026 | Jun 10, 2026 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 24,000 | — | — | 211,375 | Apr 1, 2026 | Apr 3, 2026 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 144,000 | — | — | 144,000 | Apr 1, 2026 | Apr 3, 2026 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 1,581 | $1.60 | $2.5K | 187,375 | Mar 5, 2026 | Mar 9, 2026 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 1,576 | $1.77 | $2.8K | 188,956 | Dec 5, 2025 | Dec 8, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 120,000 | $1.60 | $192.0K | 190,532 | Dec 1, 2025 | Dec 1, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 1,576 | $1.81 | $2.9K | 70,532 | Sep 5, 2025 | Dec 1, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 1,576 | $1.75 | $2.8K | 72,108 | Jun 6, 2025 | Jun 9, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 14,000 | — | — | 73,684 | Apr 1, 2025 | Apr 3, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 84,000 | — | — | 84,000 | Apr 1, 2025 | Apr 3, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 1,808 | $1.87 | $3.4K | 59,684 | Mar 5, 2025 | Mar 7, 2025 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 1,559 | $1.86 | $2.9K | 61,492 | Dec 5, 2024 | Dec 6, 2024 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | SALE Chief Financial Officer | 6,265 | $2.88 | $18.0K | 63,051 | Sep 5, 2024 | Sep 6, 2024 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 69,316 | — | — | 69,316 | Apr 1, 2024 | Apr 3, 2024 ↗ | View → |
| MGX METAGENOMI THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 291,450 | — | — | 291,450 | Apr 1, 2024 | Apr 3, 2024 ↗ | View → |